Literature DB >> 35508657

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.

Giacomo Oliveira1,2, Kari Stromhaug3, Nicoletta Cieri3, J Bryan Iorgulescu3,4,5, Susan Klaeger6, Jacquelyn O Wolff7, Suzanna Rachimi6, Vipheaviny Chea8, Kate Krause9, Samuel S Freeman4,6, Wandi Zhang3, Shuqiang Li6,8, David A Braun3,4,6,10, Donna Neuberg11, Steven A Carr6, Kenneth J Livak3,8, Dennie T Frederick6,12, Edward F Fritsch3,6, Megan Wind-Rotolo13, Nir Hacohen4,6,12, Moshe Sade-Feldman6,12, Charles H Yoon3,14, Derin B Keskin3,8,15,16, Patrick A Ott3,4,6,17, Scott J Rodig5,17, Genevieve M Boland4,6,9, Catherine J Wu18,19,20,21.   

Abstract

Within the tumour microenvironment, CD4+ T cells can promote or suppress antitumour responses through the recognition of antigens presented by human leukocyte antigen (HLA) class II molecules1,2, but how cancers co-opt these physiologic processes to achieve immune evasion remains incompletely understood. Here we performed in-depth analysis of the phenotype and tumour specificity of CD4+ T cells infiltrating human melanoma specimens, finding that exhausted cytotoxic CD4+ T cells could be directly induced by melanoma cells through recognition of HLA class II-restricted neoantigens, and also HLA class I-restricted tumour-associated antigens. CD4+ T regulatory (TReg) cells could be indirectly elicited through presentation of tumour antigens via antigen-presenting cells. Notably, numerous tumour-reactive CD4+ TReg clones were stimulated directly by HLA class II-positive melanoma and demonstrated specificity for melanoma neoantigens. This phenomenon was observed in the presence of an extremely high tumour neoantigen load, which we confirmed to be associated with HLA class II positivity through the analysis of 116 melanoma specimens. Our data reveal the landscape of infiltrating CD4+ T cells in melanoma and point to the presentation of HLA class II-restricted neoantigens and direct engagement of immunosuppressive CD4+ TReg cells as a mechanism of immune evasion that is favoured in HLA class II-positive melanoma.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35508657     DOI: 10.1038/s41586-022-04682-5

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  49 in total

Review 1.  Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity.

Authors:  Federica Sallusto; Antonio Lanzavecchia
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

Review 2.  CD4+ T cell help in cancer immunology and immunotherapy.

Authors:  Jannie Borst; Tomasz Ahrends; Nikolina Bąbała; Cornelis J M Melief; Wolfgang Kastenmüller
Journal:  Nat Rev Immunol       Date:  2018-10       Impact factor: 53.106

Review 3.  Regulatory T cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Cell Res       Date:  2016-12-20       Impact factor: 25.617

4.  Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Authors:  Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

Review 5.  Expanding roles for CD4⁺ T cells in immunity to viruses.

Authors:  Susan L Swain; K Kai McKinstry; Tara M Strutt
Journal:  Nat Rev Immunol       Date:  2012-01-20       Impact factor: 53.106

6.  Peripheral T cell expansion predicts tumour infiltration and clinical response.

Authors:  Thomas D Wu; Shravan Madireddi; Patricia E de Almeida; Romain Banchereau; Ying-Jiun J Chen; Avantika S Chitre; Eugene Y Chiang; Hina Iftikhar; William E O'Gorman; Amelia Au-Yeung; Chikara Takahashi; Leonard D Goldstein; Chungkee Poon; Shilpa Keerthivasan; Denise E de Almeida Nagata; Xiangnan Du; Hyang-Mi Lee; Karl L Banta; Sanjeev Mariathasan; Meghna Das Thakur; Mahrukh A Huseni; Marcus Ballinger; Ivette Estay; Patrick Caplazi; Zora Modrusan; Lélia Delamarre; Ira Mellman; Richard Bourgon; Jane L Grogan
Journal:  Nature       Date:  2020-02-26       Impact factor: 69.504

7.  Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

Authors:  David Y Oh; Serena S Kwek; Siddharth S Raju; Tony Li; Elizabeth McCarthy; Eric Chow; Dvir Aran; Arielle Ilano; Chien-Chun Steven Pai; Chiara Rancan; Kathryn Allaire; Arun Burra; Yang Sun; Matthew H Spitzer; Serghei Mangul; Sima Porten; Maxwell V Meng; Terence W Friedlander; Chun Jimmie Ye; Lawrence Fong
Journal:  Cell       Date:  2020-06-03       Impact factor: 41.582

8.  Clonal replacement of tumor-specific T cells following PD-1 blockade.

Authors:  Kathryn E Yost; Ansuman T Satpathy; Daniel K Wells; Yanyan Qi; Chunlin Wang; Robin Kageyama; Katherine L McNamara; Jeffrey M Granja; Kavita Y Sarin; Ryanne A Brown; Rohit K Gupta; Christina Curtis; Samantha L Bucktrout; Mark M Davis; Anne Lynn S Chang; Howard Y Chang
Journal:  Nat Med       Date:  2019-07-29       Impact factor: 53.440

9.  Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.

Authors:  Amélie Cachot; Mariia Bilous; Yen-Cheng Liu; Xiaokang Li; Margaux Saillard; Mara Cenerenti; Georg Alexander Rockinger; Tania Wyss; Philippe Guillaume; Julien Schmidt; Raphaël Genolet; Giuseppe Ercolano; Maria Pia Protti; Walter Reith; Kalliopi Ioannidou; Laurence de Leval; Joseph A Trapani; George Coukos; Alexandre Harari; Daniel E Speiser; Alexander Mathis; David Gfeller; Hatice Altug; Pedro Romero; Camilla Jandus
Journal:  Sci Adv       Date:  2021-02-26       Impact factor: 14.136

10.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Authors:  Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; John P Ray; Carl G de Boer; Russell W Jenkins; David J Lieb; Jonathan H Chen; Dennie T Frederick; Michal Barzily-Rokni; Samuel S Freeman; Alexandre Reuben; Paul J Hoover; Alexandra-Chloé Villani; Elena Ivanova; Andrew Portell; Patrick H Lizotte; Amir R Aref; Jean-Pierre Eliane; Marc R Hammond; Hans Vitzthum; Shauna M Blackmon; Bo Li; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Zachary A Cooper; Cloud P Paweletz; David A Barbie; Anat Stemmer-Rachamimov; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

View more
  4 in total

Review 1.  Cancer vaccines: Building a bridge over troubled waters.

Authors:  MacLean C Sellars; Catherine J Wu; Edward F Fritsch
Journal:  Cell       Date:  2022-07-13       Impact factor: 66.850

2.  Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.

Authors:  Denise Lau; Sonal Khare; Michelle M Stein; Prerna Jain; Yinjie Gao; Aicha BenTaieb; Tim A Rand; Ameen A Salahudeen; Aly A Khan
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

3.  Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells.

Authors:  Yanling Liang; Qumiao Xu; Songming Liu; Jie Li; Fei Wang; Ziyi Li; Lijuan Liao; Yuting Lu; Yijian Li; Feng Mu; Hai-Xi Sun; Linnan Zhu
Journal:  Front Immunol       Date:  2022-07-19       Impact factor: 8.786

Review 4.  The Roles of RUNX Proteins in Lymphocyte Function and Anti-Tumor Immunity.

Authors:  Wooseok Seo; Aneela Nomura; Ichiro Taniuchi
Journal:  Cells       Date:  2022-10-03       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.